Interferon

When ATH:
S01AD05

Pharmacological action.
Antiviral, immunomodulatory, antitumor, antiproliferative.

Application.

Volosatokletochnыy leukemia, chronic myelogenous leukemia, viral hepatitis b, active viral hepatitis C, primary (essencialny) and secondary thrombocytosis, transitional form of chronic granulocytic leukemia and myelofibrosis, mnozhestvennaya myeloma, kidney cancer; AIDS-related Kaposi's sarcoma, granulosarcoid, retikulosarkoma, multiple sclerosis, prevention and treatment of influenza and acute respiratory viral infections.

Contraindications.

Hypersensitivity, severe heart disease (incl. history), acute myocardial infarction, expressed human liver, kidney or hematopoietic system, epilepsy and / or other CNS disorders; on the background of chronic hepatitis decompensated cirrhosis; chronic hepatitis patients, receiving or shortly before receiving immunosuppressive therapy (Except for a brief pre-treatment with steroids).

Restrictions apply.

Pregnancy, lactation (should stop breastfeeding), childhood.

Side effects.

Slackness, fever, chills, loss of appetite, muscle aches, headache, joint pain, Sweating, nausea, vomiting, change in taste, dry mouth, weight loss, diarrhea, stomach ache, constipation, flatulence, increased peristalsis, heartburn, abnormal liver function, hepatitis, dizziness, visual disturbances, ishemicheskaya retinopathy, depression, drowsiness, disturbance of consciousness, nervousness, sleep disturbance, allergic skin reactions (rash, itch).

Cooperation.

Violates the metabolism of cimetidine, phenytoin, varfarina, teofillina, diazepama, propranolol.

Dosing and Administration.

/ M, n / a, intranasally. Volosatokletochnыy leukemia: the initial dose - 3 million IU per day for 16–24 weeks, Supporting treatment - 3 ME million 3 times a week. Cutaneous T-cell lymphoma: 1–3 days - 3 Milln IU per day, 4–6 day - 9 Milln IU per day, 7–84 day - 18 Milln IU per day; supportive treatment - the most tolerated dose (no more 18 ME million) 3 times a week. Kaposi's sarcoma on the background of AIDS: the initial dose 3 million IU per day in the first 3 day, 4–6 day - 9 Milln IU per day, 7–9 day - 18 Milln IU per day, With a tolerance, the dose is increased to 36 Milln IU for 10–84 days; supportive treatment - the most tolerated dose (but not more 36 ME million) 3 times a week. Pochechnokletochnыy cancer: 36 million IU per day with monotherapy or 18 ME million 3 once a week in combination with vinblastine. The dose is increased gradually, scheme, beginning with 3 b 84 days. Melanoma - 18 ME million 3 times per week for 8-12 weeks. Chronic myelogenous leukemia and thrombocytosis in chronic myeloid leukemia: 1–3 days - 3 Milln IU per day, 4–6 day - 6 Milln IU per day, 7–84 day - 9 Milln IU per day, Course - 8-12 weeks. Thrombocytosis in the myeloproliferative disorders, except for chronic myeloid leukemia: 1–3 days - 3 Milln IU per day, 4–30 day - 6 Milln IU per day. Chronic active hepatitis B - 4,5 ME million 3 once a week for 6 Months. Chronic hepatitis C: the initial dose - 6 ME million 3 once a week for 3 Months; maintenance dose - 3 ME million 3 twice a week for an additional 3 Months. With primary and secondary thrombocytosis, it is prescribed at the beginning of treatment for 2 Mills ME 5 days a week for 4-5 weeks. If the number of platelets through 2 Weeks will not decrease, increase the dose to 3 Mills ME, In the absence of the effect by the end of the third week, the dose is increased to 6 Mills ME. When the initial thrombocytopenia (less 15 G / l) the initial dose - 0,5 ME million. With the transition phase of chronic granulocytic leukemia and myelofibrosis, 1-3 million IU are prescribed per day according to the scheme, With multiple myeloma - by 1 Milln IU, a day in combination with cytostatics and corticosteroids at least 2 Months.

Intranasal - for the treatment of influenza and acute respiratory viral infusion.

Precautions.

Avoid combinations with drugs, acting on the central nervous system, immunosuppressants. Throughout the course you need to control the content of blood cells and liver function. To mitigate the side effects (flu-like symptoms) to the simultaneous administration of paracetamol.